Exploring the potential for gene therapy in Cav1.4-related retinal channelopathies

TL;DR

This paper reviews how gene therapy might help treat retinal diseases caused by faulty Cav1.4 calcium channels.

Contribution

The paper critically examines animal models and gene therapy strategies for Cav1.4-related retinal channelopathies.

Findings

Cav1.4 channel dysfunction is linked to specific visual impairments.

Animal models have provided insights but have limitations in modeling human retinal diseases.

Current gene therapy approaches face significant challenges in treating these conditions.

Abstract

The visual process begins with photon detection in photoreceptor outer segments within the retina, which processes light signals before transmission to the thalamus and visual cortex. Cav1.4 L-type calcium channels play a crucial role in this process, and dysfunction of these channels due to pathogenic variants in corresponding genes leads to specific manifestations in visual impairments. This review explores the journey from basic research on Cav1.4 L-type calcium channel complexes in retinal physiology and pathophysiology to their potential as gene therapy targets. Moreover, we provide a concise overview of key findings from studies using different animal models to investigate retinal diseases. It will critically examine the constraints these models present when attempting to elucidate retinal channelopathies. Additionally, the paper will explore potential strategies for addressing Cav1.4 channel dysfunction and discuss the current challenges facing gene therapy approaches in this area of research.

Figures